Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Diabetes: Page 3
Renalytix underscores KidneyIntelX clinical results
Specifically, the results show that these physicians understand the value of the test in determining treatment decisions for adults with type 2 diabetes and early chronic kidney disease stages 1 to 3, also known as diabetic kidney disease, the firm said.
August 7, 2022
Roche H1 diagnostics revenues up 10% year over year
The firm posted core laboratory revenues of CHF 3.88 billion, up 3% year-over-year from CHF 3.77 billion; point-of-care revenues of CHF 2.61 billion, up 45% year-over-year from CHF 1.80 billion; molecular laboratory revenues of CHF 1.98 billion, down 1% year-over-year from CHF 1.99 billion; diabetes care revenues for CHF 832 million, down 7% year-over-year from CHF 894 million; and pathology laboratory revenues of CHF 652 million, up 11% year-over-year from CHF 590 million.
July 20, 2022
GBS study compares glucose levels in saliva, blood
The developer of a biosensor platform for point-of-care testing said it will now perform statistical analyses of the correlation of glucose levels among the sample types.
July 13, 2022
Clinics begin adopting Genetic Technologies risk test
The clinics can focus on testing for a single disease or multiple diseases, including breast cancer, colorectal cancer, ovarian cancer, coronary artery disease, prostate cancer, and type 2 diabetes, the company said.
June 30, 2022
Abbott to develop new glucose-ketone monitoring system
The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation for the device, which will be the same size as the company's FreeStyle Libre 3 sensor, it said.
June 5, 2022
LumiraDx diabetes test receives CE Mark
The LumiraDx HbA1c test is used with the LumiraDx Platform for monitoring individuals with diabetes and provides results in less than seven minutes from sample application. The test is further used as an aid in screening and identifying patients who may be at risk for developing diabetes at the point of care, the company said.
June 1, 2022
COVID-19 testing offers chance for diabetes screening, too
Study investigators hypothesized that they could leverage the existing COVID-19 testing infrastructure to also test for prediabetes and diabetes in a Latinx community that might otherwise face substantial barriers to care engagement.
May 26, 2022
Levels launches on-demand blood testing service
The Metabolic Health Panel is currently available to all Levels members. Other lab tests include hemoglobin A1C, total cholesterol, low-density lipoprotein, cholesterol, high-density lipoprotein cholesterol, triglycerides, and high-sensitivity c-reactive protein.
March 28, 2022
Know Labs approved for glucose monitoring clinical trial
The trial will see blood glucose readings taken every five minutes for participants through a fingerstick device over a period of three to five hours. Participants will drink a glucola drink with 75 g of sugar, which should change their respective blood glucose levels. The Bio-RFID prototype will then measure these changes.
February 3, 2022
Quest introduces personal health panel
Quest's Comprehensive Health Profile is like a credit score for an individual's health, Quest said. The panel combines many of the tests and biometric screenings that a physician would typically order as part of an annual physical, such as a complete blood count, comprehensive metabolic panel, urinalysis, cardiovascular and diabetes risk assessment, plus others, such as inflammation, Quest said.
January 19, 2022
Diabetes testing market poised for growth
However, technological advances and increased knowledge of diabetes have led to two new areas driving the diabetes testing market: continuous glucose monitoring (CGM) and hemoglobin A1c (HbA1c) testing.
November 1, 2021
Millions of diabetes blood tests missed during U.K. lockdown
After extrapolating estimates from six laboratory testing centers across the U.K., researchers determined that approximately 2.5Â million diagnostic diabetes blood tests -- an average of 400,000 each month -- were missed or delayed during the six-month lockdown in the U.K. These missed tests resulted in 23,000 missed prediabetes diagnoses and 68,500 missed diabetes diagnoses, according to the EASD.
September 26, 2021
Previous Page
Page 3 of 7
Next Page